|
|
 |
|
|
 |
Sources and Prices of Selected Medicines and Diagnostics for People Living with HIV/AIDS (2004; 134 pages) Índice de contenido
4. Prices of medicines and diagnostics
4.1 Medicines
Table 1. Anti-infective medicines
| |
Manufacturer |
Indicative prices, US$ |
List prices, US$ |
| |
No of manuf |
No of countries |
unit |
max |
min |
median |
25th perc |
|
|
Anthelminthics |
|
|
|
|
|
|
|
Brazil |
Spain |
albendazole |
|
|
|
|
|
|
|
|
|
chewable tablet, 400 mg |
10 |
5 |
tab |
0.180 |
0.015 |
0.036 |
0.022 |
0.048 |
1.317 |
Antibacterials, beta lactam medicines |
|
|
|
|
|
|
|
|
|
benzathine benzylpenicillin |
|
|
|
|
|
|
|
|
|
powder for injection, 1.44 g (=2.4 million IU) in 24-ml vial |
1 |
1 |
vial |
0.257 |
0.257 |
0.257 |
0.257 |
none |
n/a |
powder for injection, 1.44 g (=2.4 million IU) in 5-ml vial |
3 |
3 |
vial |
1.660 |
0.150 |
0.170 |
0.160 |
none |
2.871 |
benzylpenicillin |
|
|
|
|
|
|
|
|
|
powder for injection, 3 g (=5 million IU) (as sodium or potassium salt) in vial |
3 |
3 |
vial |
0.346 |
0.150 |
0.180 |
0.165 |
0.619 |
1.211 |
powder for injection, 600 mg (=1 million IU) (as potasium salt) in vial |
1 |
1 |
vial |
0.268 |
0.268 |
0.268 |
0.268 |
none |
n/a |
cefixime |
|
|
|
|
|
|
|
|
|
paediatric oral suspension, 100 mg/5 ml |
3 |
3 |
ml |
0.201 |
0.025 |
0.034 |
0.030 |
none |
1.856 |
paediatric oral suspension, 40 mg/5 ml |
1 |
1 |
ml |
0.108 |
0.108 |
0.108 |
0.108 |
none |
n/a |
powder for injection, 250 mg (as sodium salt)* |
- |
- |
vial |
|
|
|
|
none |
n/a |
tablet, 200 mg |
3 |
2 |
tab |
1.213 |
0.315 |
0.375 |
0.345 |
none |
0.935 |
tablet, 400 mg |
2 |
2 |
tab |
0.560 |
0.165 |
0.363 |
0.264 |
none |
1.713 |
ceftriaxone |
|
|
|
|
|
|
|
|
|
powder for injection, 1 g (as sodium salt) in vial |
18 |
12 |
1g vial |
12.680 |
0.600 |
1.086 |
0.852 |
0.687 |
8.247 |
powder for injection, 250 mg (as sodium salt) in vial |
13 |
8 |
vial |
2.809 |
0.230 |
0.775 |
0.650 |
none |
2.684 |
powder for injection, 500 mg (as sodium salt) in vial |
11 |
8 |
vial |
8.140 |
0.320 |
0.825 |
0.756 |
none |
4.322 |
procaine benzylpenicillin |
|
|
|
|
|
|
|
|
|
powder for injection, 3 g (=3 million IU) in vial |
3 |
3 |
vial |
0.237 |
0.144 |
0.170 |
0.157 |
none |
n/a |
Other antibacterials |
azithromycin |
|
|
|
|
|
|
|
|
|
oral suspension, 200 mg/5 ml (dihydrate) |
2 |
2 |
ml |
0.200 |
0.040 |
0.120 |
0.080 |
0.078 |
0.310 |
capsule/tablet, 250 mg (dihydrate) |
8 |
4 |
caps/tab |
0.532 |
0.117 |
0.198 |
0.147 |
none |
1.685 |
capsule/tablet, 500 mg (dihydrate) |
8 |
5 |
caps/tab |
1.500 |
0.250 |
0.470 |
0.308 |
0.447 |
4.120 |
capreomycin |
|
|
|
|
|
|
|
|
|
powder for injection, 1 g in vial |
2 |
2 |
1g vial |
5.000 |
5.000 |
5.000 |
5.000 |
none |
2.730 |
chloramphenicol |
|
|
|
|
|
|
|
|
|
oily suspension for injection, 0.5 g/ml (as sodium succinate) in 2-ml ampoule |
1 |
1 |
amp |
0.620 |
0.620 |
0.620 |
0.620 |
none |
n/a |
oral suspension, 150 mg/5 ml (as palmitate) |
1 |
1 |
ml |
0.006 |
0.006 |
0.006 |
0.006 |
none |
n/a |
powder for injection, 1 g (sodium succinate) in vial |
5 |
4 |
1g vial |
0.680 |
0.175 |
0.231 |
0.200 |
0.371 |
1.055 |
ciprofloxacin |
|
|
|
|
|
|
|
|
|
tablet, 250 mg (as hydrochloride) |
29 |
16 |
tab |
0.605 |
0.011 |
0.041 |
0.018 |
0.048 |
0.227 |
tablet, 500 mg (as hydrochloride) |
24 |
14 |
tab |
1.186 |
0.022 |
0.054 |
0.027 |
0.058 |
0.421 |
clarithromycin |
|
|
|
|
|
|
|
|
|
oral suspension, 125 mg/5 ml* |
- |
- |
ml |
- |
- |
- |
- |
none |
n/a |
powder for injection, 500 mg |
1 |
1 |
vial |
0.700 |
0.700 |
0.700 |
0.700 |
none |
23.346 |
tablet, 250 mg |
15 |
10 |
tab |
0.434 |
0.105 |
0.170 |
0.151 |
0.296 |
0.600 |
clindamycin |
|
|
|
|
|
|
|
|
|
capsule, 150 mg |
2 |
2 |
caps |
0.113 |
0.036 |
0.075 |
0.055 |
0.660 |
0.164 |
injection, 150 mg/ml (as phosphate) in 2-ml ampoule |
1 |
1 |
amp |
1.848 |
1.848 |
1.848 |
1.848 |
0.464 |
1.506 |
cycloserine |
|
|
|
|
|
|
|
|
|
capsule, 250 mg |
2 |
2 |
caps |
0.600 |
0.466 |
0.533 |
0.500 |
none |
n/a |
doxycycline |
|
|
|
|
|
|
|
|
|
capsule/tablet, 100 mg (hydrochloride) |
15 |
10 |
caps/tab |
0.114 |
0.007 |
0.015 |
0.011 |
0.052 |
0.112 |
erythromycin |
|
|
|
|
|
|
|
|
|
powder for injection, 500 mg (as lactobionate) in vial* |
- |
- |
vial |
- |
- |
- |
- |
none |
n/a |
powder for oral suspension, 125 mg (as stearate or ethylsuccinate) |
10 |
9 |
ml |
0.899 |
0.005 |
0.011 |
0.008 |
0.010 |
n/a |
capsule/tablet, 250 mg (as stearate or ethylsuccinate) |
19 |
10 |
caps/tab |
0.068 |
0.020 |
0.031 |
0.026 |
none |
0.099 |
capsule/tablet, 500 mg (as stearate or ethylsuccinate) |
12 |
7 |
caps/tab |
0.126 |
0.040 |
0.051 |
0.046 |
0.099 |
0.202 |
Other antibacteriald |
gentamicin |
|
|
|
|
|
|
|
|
|
injection, 10 mg (as sulfate) in 2-ml vial |
4 |
4 |
vial |
0.295 |
0.045 |
0.073 |
0.045 |
0.072 |
n/a |
injection, 40 mg (as sulfate) in 2-ml vial |
7 |
4 |
vial |
0.319 |
0.047 |
0.058 |
0.056 |
0.065 |
0.615 |
metronidazole |
|
|
|
|
|
|
|
|
|
injection, 500 mg in 100-ml vial |
6 |
6 |
vial |
2.880 |
0.300 |
1.268 |
0.827 |
0.189 |
3.039 |
Suppository, 1 g |
1 |
1 |
sup |
0.450 |
0.450 |
0.450 |
0.450 |
none |
n/a |
Suppository, 500 mg* |
- |
- |
sup |
|
|
|
|
none |
n/a |
ofloxacin |
|
|
|
|
|
|
|
|
|
IV infusion, 2 mg/ml (hydrochloride) |
1 |
1 |
ml |
0.032 |
0.032 |
0.032 |
0.032 |
none |
17.828 |
tablet, 200 mg |
14 |
7 |
tab |
1.620 |
0.021 |
0.042 |
0.029 |
none |
0.800 |
tablet, 400 mg |
5 |
4 |
tab |
0.661 |
0.062 |
0.100 |
0.082 |
1.014 |
n/a |
rifabutin |
|
|
|
|
|
|
|
|
|
capsule, 150 mg |
1 |
1 |
caps |
0.753 |
0.753 |
0.753 |
0.753 |
none |
2.813 |
silver nitrate |
|
|
|
|
|
|
|
|
|
solution (eye drops), 1% |
1 |
1 |
ml |
0.070 |
0.070 |
0.070 |
0.070 |
none |
n/a |
spectinomycin |
|
|
|
|
|
|
|
|
|
powder for injection, 2 g (as hydrochloride) in vial |
3 |
3 |
vial |
4.000 |
2.747 |
3.750 |
3.249 |
none |
n/a |
sulfadiazine |
|
|
|
|
|
|
|
|
|
injection, 250 mg (sodium salt) in 4-ml ampoule* |
- |
- |
amp |
- |
- |
- |
- |
none |
n/a |
tablet, 500 mg |
4 |
4 |
tab |
0.298 |
0.037 |
0.060 |
0.037 |
0.018 |
0.075 |
sulfamethoxazole+trimethoprim |
|
|
|
|
|
|
|
|
|
injection, 80+16 mg/ml in 5-ml ampoule* |
- |
- |
amp |
- |
- |
- |
- |
none |
0.789 |
oral suspension, 200+40 mg/5 ml |
15 |
9 |
ml |
0.137 |
0.003 |
0.006 |
0.005 |
0.002 |
0.022 |
tablet, 100+20 mg |
9 |
7 |
tab |
0.187 |
0.004 |
0.006 |
0.005 |
none |
0.026 |
tablet, 400+80 mg |
23 |
13 |
tab |
0.187 |
0.005 |
0.010 |
0.008 |
0.016 |
0.049 |
tablet, 800+160 mg |
11 |
9 |
tab |
0.100 |
0.009 |
0.019 |
0.015 |
0.069 |
0.129 |
tetracycline |
|
|
|
|
|
|
|
|
|
tablet, 500 mg |
3 |
3 |
tab |
0.021 |
0.014 |
0.014 |
0.014 |
0.031 |
n/a |
Antifilarials |
crotamiton |
|
|
|
|
|
|
|
|
|
cream/lotion 10% |
1 |
1 |
ml |
0.010 |
0.010 |
0.010 |
0.010 |
none |
0.665 |
ivermectin |
|
|
|
|
|
|
|
|
|
scored tablet, 3 mg* |
- |
- |
tab |
- |
- |
- |
- |
none |
n/a |
scored tablet, 6 mg* |
|
|
tab |
|
|
|
|
none |
n/a |
lindane |
|
|
|
|
|
|
|
|
|
cream, lotion or powder 0.3%* |
- |
- |
tube |
- |
- |
- |
- |
none |
n/a |
permethrin |
|
|
|
|
|
|
|
|
|
cream, 5%* |
- |
- |
tube |
- |
- |
- |
- |
none |
9.201 |
lotion, 1% |
- |
- |
tube |
- |
- |
- |
- |
none |
n/a |
Antifungal medicines |
amphotericin B |
|
|
|
|
|
|
|
|
|
liposomal IV infusion, 5 mg/ml* |
- |
- |
vial |
- |
- |
- |
- |
none |
172.950 |
liposomal IV infusion, powder for reconstitution 50 mg* |
- |
- |
vial |
- |
- |
- |
- |
none |
76.089 |
powder for injection, 50 mg in vial |
2 |
2 |
vial |
9.000 |
5.181 |
7.091 |
6.136 |
2.426 |
2.567 |
clotrimazole |
|
|
|
|
|
|
|
|
|
cream, 1% |
11 |
10 |
gram |
0.240 |
0.007 |
0.027 |
0.018 |
0.653 |
1.622 |
pessary, 500 mg |
2 |
2 |
pess |
0.600 |
0.026 |
0.313 |
0.170 |
none |
2.196 |
fluconazole |
|
|
|
|
|
|
|
|
|
capsule, 50 mg |
4 |
2 |
caps |
0.744 |
0.069 |
0.242 |
0.100 |
none |
1.432 |
capsule, 150 mg |
9 |
4 |
caps |
1.840 |
0.034 |
0.500 |
0.280 |
0.151 |
4.303 |
capsule, 200 mg |
9 |
5 |
caps |
1.518 |
0.071 |
0.350 |
0.156 |
none |
5.730 |
oral suspension, 50 mg/5 ml* |
- |
- |
ml |
- |
- |
- |
- |
none |
n/a |
solution for injection, 2 mg/ml in ampoule |
5 |
2 |
ml |
0.042 |
0.029 |
0.033 |
0.029 |
0.014 |
n/a |
itraconazole |
|
|
|
|
|
|
|
|
|
capsule, 100 mg |
3 |
3 |
caps |
0.640 |
0.128 |
0.500 |
0.314 |
0.292 |
1.539 |
oral solution, 10 mg/ml* |
- |
- |
ml |
- |
- |
- |
- |
none |
2.126 |
ketoconazole |
|
|
|
|
|
|
|
|
|
cream, 2% |
7 |
5 |
gram |
0.227 |
0.014 |
0.044 |
0.022 |
none |
3.831 |
oral suspension, 100 mg/5 ml* |
- |
- |
ml |
- |
- |
- |
- |
none |
0.087 |
tablet, 200 mg |
16 |
10 |
tab |
0.122 |
0.006 |
0.042 |
0.038 |
none |
0.352 |
Antifungal medicines |
miconazole |
|
|
|
|
|
|
|
|
|
cream/ointment 2% (as nitrate) 15 g tube |
5 |
5 |
tube |
1.176 |
0.350 |
0.418 |
0.400 |
none |
n/a |
cream/ointment 2% (as nitrate) 30 g tube |
8 |
5 |
tube |
0.980 |
0.130 |
0.435 |
0.394 |
0.618 |
2.395 |
nystatin |
|
|
|
|
|
|
|
|
|
lozenge, 100,000 IU* |
- |
- |
loz |
- |
- |
- |
- |
none |
n/a |
pessary, 100,000 IU |
5 |
4 |
pess |
0.030 |
0.017 |
0.024 |
0.021 |
none |
0.071 |
tablet, 100,000 IU |
2 |
2 |
tab |
0.025 |
0.022 |
0.024 |
0.023 |
none |
0.000 |
tablet, 500,000 IU |
7 |
4 |
tab |
0.069 |
0.022 |
0.036 |
0.030 |
none |
0.081 |
Antiprotozoal medicines |
pentamidine |
|
|
|
|
|
|
|
|
|
powder for injection, 200 mg (isetionate) in vial |
1 |
1 |
vial |
9.000 |
9.000 |
9.000 |
9.000 |
none |
n/a |
tablet, 200 mg* |
- |
- |
tab |
- |
- |
- |
- |
none |
n/a |
tablet, 300 mg* |
- |
- |
tab |
- |
- |
- |
- |
none |
n/a |
powder for injection, 300 mg (isetionate) in vial |
4 |
4 |
vial |
48.400 |
9.980 |
18.350 |
11.495 |
36.948 |
10.739 |
pyrimethamine |
|
|
|
|
|
|
|
|
|
tablet, 25 mg |
2 |
2 |
tab |
0.050 |
0.045 |
0.048 |
0.046 |
0.017 |
0.079 |
tinidazole |
|
|
|
|
|
|
|
|
|
tablet, 2 g* |
- |
- |
tab |
- |
- |
- |
- |
none |
n/a |
tablet, 500 mg |
3 |
2 |
tab |
0.015 |
0.010 |
0.012 |
0.011 |
none |
0.549 |
Antiviral medicines |
aciclovir |
|
|
|
|
|
|
|
|
|
cream, 5% |
4 |
3 |
gram |
0.986 |
0.037 |
0.450 |
0.039 |
0.409 |
1.424 |
powder for injection, 250 mg (as sodium salt) in 10-ml vial |
3 |
3 |
vial |
14.286 |
2.000 |
3.451 |
2.726 |
1.457 |
4.923 |
tablet, 200 mg |
14 |
10 |
tab |
0.540 |
0.030 |
0.054 |
0.039 |
0.086 |
0.699 |
tablet, 400 mg |
12 |
8 |
tab |
0.565 |
0.048 |
0.084 |
0.062 |
none |
n/a |
tablet, 800 mg |
8 |
5 |
tab |
1.020 |
0.098 |
0.259 |
0.155 |
none |
2.115 |
cidofovir |
|
|
|
|
|
|
|
|
|
IV infusion, 75 mg/ml in vial* |
- |
- |
vial |
- |
- |
- |
- |
none |
n/a |
famciclovir |
|
|
|
|
|
|
|
|
|
tablet, 125 mg* |
- |
- |
tab |
- |
- |
- |
- |
none |
3.095 |
tablet, 250 mg* |
- |
- |
tab |
- |
- |
- |
- |
none |
5.524 |
foscarnet sodium |
|
|
|
|
|
|
|
|
|
IV infusion, 24 mg/ml |
- |
- |
vial |
- |
- |
- |
- |
none |
40.326 |
ganciclovir |
|
|
|
|
|
|
|
|
|
capsule, 250 mg* |
- |
- |
caps |
- |
- |
- |
- |
none |
4.027 |
capsule, 500 mg* |
- |
- |
caps |
- |
- |
- |
- |
none |
n/a |
powder for IV infusion, 500 mg in vial |
1 |
1 |
vial |
42.520 |
42.520 |
42.520 |
42.520 |
17.337 |
24.874 |
imiquimod |
|
|
|
|
|
|
|
|
|
cream, 5%* |
- |
- |
tube |
- |
- |
- |
- |
none |
n/a |
podofilox |
|
|
|
|
|
|
|
|
|
cream, 0.15%* |
- |
- |
tube |
- |
- |
- |
- |
none |
17.182 |
solution or gel, 0.5%* |
- |
- |
tube |
- |
- |
- |
- |
none |
11.040 |
podophyllum resin |
|
|
|
|
|
|
|
|
|
solution, 10-25%* |
- |
- |
ml |
- |
- |
- |
- |
none |
n/a |
valacyclovir |
|
|
|
|
|
|
|
|
|
tablet, 500 mg* |
- |
- |
tab |
- |
- |
- |
- |
none |
2.300 |
valganciclovir |
|
|
|
|
|
|
|
|
|
tablet, 450 mg* |
- |
- |
tab |
- |
- |
- |
- |
none |
28.090 |
Antiviral medicines - Antiretrovirals |
abacavir (ABC) |
|
|
|
|
|
|
|
|
|
syrup, 20 mg/ml |
1 |
1 |
ml |
0.131 |
0.131 |
0.131 |
0.131 |
none |
0.333 |
tablet, 300 mg |
3 |
2 |
tab |
1.983 |
1.215 |
1.404 |
1.310 |
none |
3.828 |
didanosine (ddI) |
|
|
|
|
|
|
|
|
|
buffered chewable tablet, 100 mg |
8 |
6 |
tab |
0.376 |
0.179 |
0.298 |
0.241 |
0.317 |
1.370 |
buffered chewable tablet, 25 mg |
5 |
5 |
tab |
0.286 |
0.083 |
0.108 |
0.083 |
none |
0.342 |
syrup, 2 g |
2 |
2 |
ml |
0.171 |
0.125 |
0.148 |
0.137 |
none |
27.402 |
unbuffered enteric coated capsule, 125 mg* |
- |
- |
caps |
- |
- |
- |
- |
none |
2.139 |
unbuffered enteric coated capsule, 250 mg |
2 |
1 |
caps |
0.666 |
0.648 |
0.657 |
0.653 |
none |
3.923 |
unbuffered enteric coated capsule, 400 mg |
2 |
1 |
caps |
1.008 |
0.928 |
0.968 |
0.948 |
none |
5.596 |
efavirenz (EFZ) |
|
|
|
|
|
|
|
|
|
capsule, 50 mg* |
- |
- |
caps |
- |
- |
- |
- |
none |
n/a |
capsule, 200 mg |
4 |
2 |
caps |
2.001 |
0.490 |
0.540 |
0.518 |
none |
n/a |
tablet, 600 mg |
3 |
1 |
tab |
1.582 |
1.300 |
1.467 |
1.384 |
2.182 |
n/a |
indinavir (IDV) |
|
|
|
|
|
|
|
|
|
capsule, 200 mg |
3 |
3 |
caps |
0.600 |
0.166 |
0.312 |
0.239 |
none |
0.966 |
capsule, 400 mg |
6 |
3 |
caps |
1.058 |
0.301 |
0.341 |
0.308 |
0.404 |
1.934 |
lamivudine (3TC) |
|
|
|
|
|
|
|
|
|
syrup, 50 mg/5 ml |
3 |
3 |
ml |
0.028 |
0.025 |
0.025 |
0.025 |
0.035 |
0.208 |
tablet, 150 mg |
13 |
8 |
tab |
1.531 |
0.086 |
0.150 |
0.124 |
0.237 |
3.129 |
tablet, 300 mg |
1 |
1 |
tab |
0.316 |
0.316 |
0.316 |
0.316 |
none |
n/a |
nelfinavir (NFV) |
|
|
|
|
|
|
|
|
|
capsule, 250 mg |
6 |
4 |
caps |
1.340 |
0.269 |
0.520 |
0.311 |
0.611 |
1.453 |
powder for suspension, 50 mg/g* |
- |
- |
g |
- |
- |
- |
- |
none |
0.466 |
nevirapine (NVP) |
|
|
|
|
|
|
|
|
|
syrup, 50 mg/5 ml |
3 |
2 |
ml |
0.100 |
0.015 |
0.031 |
0.023 |
0.143 |
0.225 |
tablet, 200 mg |
10 |
7 |
tab |
1.984 |
0.133 |
0.257 |
0.173 |
none |
4.426 |
saquinavir (SQV) |
|
|
|
|
|
|
|
|
|
capsule, 200 mg |
2 |
1 |
caps |
0.286 |
0.283 |
0.285 |
0.284 |
none |
1.328 |
stavudine (d4T) |
|
|
|
|
|
|
|
|
|
capsule, 15 mg |
2 |
2 |
caps |
0.095 |
0.058 |
0.077 |
0.067 |
none |
2.608 |
capsule, 20 mg |
4 |
3 |
caps |
0.101 |
0.051 |
0.082 |
0.065 |
none |
2.705 |
capsule, 30 mg |
11 |
7 |
caps |
0.140 |
0.047 |
0.068 |
0.065 |
0.093 |
2.830 |
capsule, 40 mg |
15 |
10 |
caps |
2.101 |
0.058 |
0.101 |
0.079 |
0.182 |
2.925 |
syrup, 1 mg/ml |
3 |
3 |
ml |
0.050 |
0.011 |
0.048 |
0.049 |
none |
0.596 |
tenofovir (TDF) |
|
|
|
|
|
|
|
|
|
tablet, 300 mg* |
- |
- |
tab |
- |
- |
- |
- |
none |
12.797 |
zalcitabine (ddC) |
|
|
|
|
|
|
|
|
|
tablet, 0.375 mg |
1 |
1 |
tab |
0.402 |
0.402 |
0.402 |
0.402 |
none |
n/a |
tablet, 0.75 mg |
2 |
2 |
tab |
0.865 |
0.761 |
0.813 |
0.787 |
none |
1.757 |
zidovudine (AZT or ZDV) |
|
|
|
|
|
|
|
|
|
capsule, 100 mg |
14 |
10 |
caps |
0.617 |
0.084 |
0.142 |
0.113 |
0.114 |
1.097 |
capsule, 250 mg |
7 |
6 |
caps |
1.450 |
0.307 |
0.450 |
0.346 |
none |
2.051 |
tablet, 300 mg |
9 |
6 |
tab |
0.624 |
0.242 |
0.290 |
0.252 |
none |
2.462 |
injection, 10 mg/ml in 20-ml vial |
1 |
1 |
vial |
5.000 |
5.000 |
5.000 |
5.000 |
1.443 |
8.532 |
oral solution, 50 mg/5 ml |
3 |
3 |
ml |
0.036 |
0.019 |
0.026 |
0.023 |
0.015 |
0.085 |
3TC/AZT |
|
|
|
|
|
|
|
|
|
tablet, 300/150 mg |
11 |
7 |
tab |
2.951 |
0.278 |
0.384 |
0.328 |
0.471 |
8.036 |
3TC/D4T/NVP |
|
|
|
|
|
|
|
|
|
tablet, 150/30/200 mg |
1 |
1 |
tab |
0.431 |
0.431 |
0.431 |
0.431 |
none |
n/a |
tablet, 150/40/200 mg |
6 |
4 |
tab |
0.496 |
0.275 |
0.402 |
0.346 |
none |
n/a |
ABC/3TC/ZDV |
|
|
|
|
|
|
|
|
|
tablet, 300/150/300 mg |
2 |
2 |
tab |
2.294 |
1.700 |
1.997 |
1.849 |
none |
13.566 |
AZT/3TC/NVP |
|
|
|
|
|
|
|
|
|
tablet, 300/150/200 mg |
2 |
1 |
tab |
0.499 |
0.463 |
0.481 |
0.472 |
none |
n/a |
lopinavir/ritonavir (LPV/r) |
|
|
|
|
|
|
|
|
|
oral solution, 20+80 mg/ml* |
- |
- |
ml |
- |
- |
- |
- |
none |
8.060 |
capsule, 133.3+33.3 mg* |
- |
- |
caps |
- |
- |
- |
- |
none |
2.687 |
* No price information
none - no purchase has been made for this product, therefore no minimum price payable is available
n/a - not available
Table 2. Antineoplastic medicines
| |
Manufacturer |
Indicative prices, US$ |
List prices, US$ |
Cytotoxic medicines |
No of manuf |
No of countries |
unit |
max |
min |
median |
25th perc |
Brazil |
Spain |
bleomycin |
|
|
|
|
|
|
|
|
|
powder for injection, 15 mg (as sulfate) in vial |
2 |
2 |
vial |
21.000 |
18.000 |
19.500 |
18.750 |
22.515 |
13.930 |
calcium folinate (leucovorin) |
|
|
|
|
|
|
|
|
|
tablet, 15 mg |
3 |
3 |
tab |
3.496 |
0.012 |
2.561 |
1.287 |
none |
0.767 |
doxorubicine HCl |
|
|
|
|
|
|
|
|
|
powder for injection, 10 mg in 5-ml vial |
4 |
4 |
vial |
23.720 |
3.000 |
7.660 |
5.063 |
3.196 |
7.286 |
powder for injection, 50 mg in 25-ml vial |
4 |
4 |
vial |
111.111 |
14.000 |
29.525 |
17.675 |
14.739 |
31.858 |
etoposide |
|
|
|
|
|
|
|
|
|
capsule, 100 mg* |
|
- caps |
|
|
|
|
|
none |
11.566 |
injection, 20 mg/ml in 5-ml ampoule |
5 |
3 |
amp |
31.211 |
1.723 |
9.850 |
5.000 |
2.921 |
2.492 |
methotrexate |
|
|
|
|
|
|
|
|
|
injection, 25 mg/ml (as sodium salt) in 2-ml vial |
2 |
2 |
vial |
18.100 |
1.400 |
9.750 |
5.575 |
2.062 |
3.603 |
powder for injection, 50 mg (as sodium salt) in 2-ml vial |
3 |
3 |
vial |
4.310 |
2.000 |
3.360 |
2.680 |
none |
3.772 |
tablet, 2.5 mg |
4 |
3 |
tab |
0.188 |
0.031 |
0.068 |
0.057 |
none |
0.056 |
vinblastine |
|
|
|
|
|
|
|
|
|
powder for injection, 10 mg (sulfate) in 10-ml vial |
3 |
2 |
vial |
14.260 |
1.400 |
2.347 |
1.874 |
11.684 |
6.815 |
vincristine |
|
|
|
|
|
|
|
|
|
injection, 1 mg/ml (sulfate) in vial |
3 |
3 |
vial |
4.500 |
0.674 |
3.080 |
1.877 |
2.405 |
n/a |
powder for injection, 1 mg (sulfate) in 1-ml vial |
1 |
1 |
vial |
2.000 |
2.000 |
2.000 |
2.000 |
2.405 |
5.468 |
vinorelbine |
|
|
|
|
|
|
|
|
|
injection concentrate 10 mg/ml in vial |
1 |
1 |
ml |
16.480 |
16.480 |
16.480 |
16.480 |
143.086 |
21.352 |
Table 3. Medicines used for the treatment of mental and substance use disorders
| |
Manufacturer |
Indicative prices, US$ |
List prices, US$ |
Medicines used in depressive disorders |
No of manuf |
No of countries |
unit |
max |
min |
median |
25th perc |
Brazil |
Spain |
amitriptyline |
|
|
|
|
|
|
|
|
|
tablet, 25 mg (as hydrochloride) |
9 |
5 |
tab |
0.065 |
0.004 |
0.008 |
0.007 |
0.010 |
0.03 |
fluoxetine |
|
|
|
|
|
|
|
|
|
tablet, 20 mg |
10 |
7 |
tab |
0.491 |
0.015 |
0.078 |
0.040 |
0.034 |
0.221 |
Medicines used in generalized anxiety and sleep disorders |
|
|
|
|
|
|
|
|
|
lorazepam |
|
|
|
|
|
|
|
|
|
injection, 4 mg/ml in ampoule* |
- |
- |
amp |
- |
- |
- |
- |
none |
n/a |
tablet, 1 mg* |
- |
- |
tab |
- |
- |
- |
- |
none |
0.027 |
methotrimepazine/levomepromazine |
|
|
|
|
|
|
|
|
|
injection, 25 mg/ml in ampoule |
- |
- |
amp |
- |
- |
- |
- |
none |
0.181 |
tablet, 25 mg |
2 |
2 |
tab |
0.108 |
0.033 |
0.071 |
0.052 |
0.038 |
0.059 |
Medicines used in the treatment of opioid dependence |
buprenorphine |
|
|
|
|
|
|
|
|
|
sublingual tablet, 200 mcg (hydrochloride)* |
- |
- |
tab |
- |
- |
- |
- |
none |
0.370 |
sublingual tablet, 400 mcg (hydrochloride)* |
- |
- |
tab |
- |
- |
- |
- |
none |
n/a |
naltrexone HCl |
|
|
|
|
|
|
|
|
|
tablet, 50 mg |
2 |
2 |
tab |
1.277 |
0.875 |
1.076 |
0.976 |
none |
2.444 |
Opioid analgesics |
codeine |
|
|
|
|
|
|
|
|
|
tablet, 30 mg (phosphate) |
5 |
5 |
tab |
0.066 |
0.020 |
0.034 |
0.030 |
0.232 |
0.100 |
methadone |
|
|
|
|
|
|
|
|
|
tablet, 5 mg |
1 |
1 |
tab |
0.185 |
0.185 |
0.185 |
0.185 |
none |
0.055 |
morphine |
|
|
|
|
|
|
|
|
|
injection, 10 mg/ml (sulfate or HCl), in 1-ml ampoule |
6 |
4 |
amp |
1.998 |
0.271 |
0.470 |
0.311 |
0.495 |
0.231 |
oral solution, 10 mg/5 ml (sulfate or HCl) |
4 |
2 |
ml |
1.000 |
0.055 |
0.058 |
0.056 |
none |
n/a |
tablet, modified release, 10 mg (sulfate) |
|
|
tab |
|
|
|
|
none |
0.137 |
pethidine |
|
|
|
|
|
|
|
|
|
injection, 50 mg/ml (hydrochloride) in 1-ml ampoule |
4 |
3 |
amp |
0.450 |
0.284 |
0.370 |
0.334 |
0.344 |
n/a |
injection, 50 mg/ml (hydrochloride) in 2-ml ampoule |
7 |
6 |
amp |
1.773 |
0.258 |
0.505 |
0.392 |
none |
0.598 |
tablet, 50 mg |
2 |
1 |
tab |
0.130 |
0.125 |
0.128 |
0.129 |
none |
n/a |
tablet, 100 mg |
1 |
1 |
tab |
0.150 |
0.150 |
0.150 |
0.150 |
none |
n/a |
* No price information
none - no purchase has been made for this product, therefore no minimum price payable is available
n/a - not available
Table 4. Analgesics
| |
Manufacturer |
Indicative prices, US$ |
List prices, US$ |
Opioid analgesics |
No of manuf |
No of countries |
unit |
max |
min |
median |
25th perc |
Brazil |
Spain |
codeine |
|
|
|
|
|
|
|
|
|
tablet, 30 mg (phosphate) |
5 |
5 |
tab |
0.066 |
0.020 |
0.034 |
0.030 |
0.232 |
0.100 |
methadone |
|
|
|
|
|
|
|
|
|
tablet, 5 mg |
1 |
1 |
tab |
0.185 |
0.185 |
0.185 |
0.185 |
none |
0.055 |
morphine |
|
|
|
|
|
|
|
|
|
injection, 10 mg/ml (sulfate or HCl), in 1-ml ampoule |
6 |
4 |
amp |
1.998 |
0.271 |
0.470 |
0.311 |
0.495 |
0.231 |
oral solution, 10 mg/5 ml (sulfate or HCl) |
4 |
2 |
ml |
1.000 |
0.055 |
0.058 |
0.056 |
none |
n/a |
tablet, modified release, 10 mg (sulfate) |
|
|
tab |
|
|
|
|
none |
0.137 |
pethidine |
|
|
|
|
|
|
|
|
|
injection, 50 mg/ml (hydrochloride) in 1-ml ampoule |
4 |
3 |
amp |
0.450 |
0.284 |
0.370 |
0.334 |
0.344 |
n/a |
injection, 50 mg/ml (hydrochloride) in 2-ml ampoule |
7 |
6 |
amp |
1.773 |
0.258 |
0.505 |
0.392 |
none |
0.598 |
tablet, 50 mg |
2 |
1 |
tab |
0.130 |
0.125 |
0.128 |
0.129 |
none |
n/a |
tablet, 100 mg |
1 |
1 |
tab |
0.150 |
0.150 |
0.150 |
0.150 |
none |
n/a |
Table 5. Gastrointestinal medicines
| |
Manufacturer |
Indicative prices, US$ |
List prices, US$ |
Antacids and other antiulcer medicines |
No of manuf |
No of countries |
unit |
max |
min |
median |
25th perc |
Brazil |
Spain |
omeprazole |
|
|
|
|
|
|
|
|
|
capsule, 10 mg |
8 |
6 |
caps |
0.312 |
0.014 |
0.070 |
0.050 |
0.028 |
n/a |
capsule, 20 mg |
19 |
9 |
caps |
1.046 |
0.011 |
0.093 |
0.030 |
0.034 |
0.210 |
capsule, 40 mg |
10 |
6 |
caps |
1.207 |
0.030 |
0.177 |
0.088 |
none |
0.905 |
powder for injection, 40 mg (as sodium salt) in vial |
1 |
1 |
vial |
3.000 |
3.000 |
3.000 |
3.000 |
1.371 |
9.584 |
powder for IV infusion, 40 mg (as sodium salt) in vial |
2 |
2 |
vial |
3.000 |
1.950 |
2.475 |
2.213 |
none |
n/a |
Antiemetic medicines |
dimenhydrinate |
|
|
|
|
|
|
|
|
|
tablet, 50 mg |
4 |
4 |
tab |
0.056 |
0.005 |
0.025 |
0.010 |
none |
0.129 |
metoclopramide |
|
|
|
|
|
|
|
|
|
injection 5 mg/ml in 2-ml ampoule |
5 |
5 |
amp |
0.219 |
0.055 |
0.112 |
0.108 |
0.062 |
0.177 |
tablet, 10 mg (as hydrochloride) |
9 |
7 |
tab |
0.027 |
0.002 |
0.007 |
0.006 |
0.005 |
0.050 |
prochlorperazine |
|
|
|
|
|
|
|
|
|
injection, 12.5 mg/ml |
2 |
2 |
ml |
0.359 |
0.130 |
0.245 |
0.187 |
none |
n/a |
tablet, 5 mg |
3 |
3 |
tab |
0.009 |
0.004 |
0.008 |
0.006 |
none |
n/a |
Laxatives |
|
|
|
|
|
|
|
|
|
docusate sodium |
|
|
|
|
|
|
|
|
|
capsule, 100 mg* |
- |
- |
tab |
- |
- |
- |
- |
none |
n/a |
* No price information
none - no purchase has been made for this product, therefore no minimum price payable is available
n/a - not available
4.2 UN Bulk Procurement Scheme 2004: Specifications of HIV test kits - Simple/Rapid,Elisa and Supplemental Assays
SIMPLE/RAPID ASSAYS
Assay name (Manufacturer) |
Company’s Order Code |
No. of tests per kit |
Guaranteed Shelf-life/Storage temp (°C) |
HIV type1 |
Assay type Antigen |
Sample type |
Equipment requirements2 |
Cost/test3 €/¥ |
Cost/test3 US $ |
BIOLINE HIV 1/2 3.0 (Standard Diagnostics Inc.) |
03FK10 |
30 |
16 months/ 2°-30° |
HIV1 HIV 2 |
lateral flow recombinant proteins |
whole blood serum/plasma |
D, G |
|
0.47 |
BIONOR HIV-1 & 2 (Bionor AS) |
DN061 |
250 |
10 months/ 2°-8° |
HIV 1+2 |
synthetic peptides |
whole blood serum/plasma |
E, G, Special Equipment |
|
1.00 |
CAPILLUS HIV-1/HIV-2 (Trinity Biotech) |
6048G |
100 |
9 months/ 2°-8° |
HIV 1+2 |
agglutination recombinant proteins |
whole blood serum/plasma |
G |
€ 1.00 |
|
DETERMINETM HIV-1/2 Abbott Diagnostics) |
7D23-13 |
100 |
6 -9 months/ 2°-30° |
HIV 1+2 |
lateral flow recombinant protein, synthetic peptide |
whole blood serum/plasma |
D, G |
|
Access countries: 0.80 Elsewhere: 1.00 |
DIAGNOSTIC KIT for HIV (1+2) ANTIBODY (COLLOIDAL GOLD) (Shanghai Kehua) (SEAR & WR only) |
KH-R-02 |
50 |
15 months/ 4°-30° |
HIV 1+2 |
lateral flow |
whole blood serum/plasma |
D, G |
|
0.60 |
FIRST RESPONSETM HIV 1-2-0 Card Test (Premier Medical Corp) |
105FRC30 |
30 |
15 months/ 2°-30° |
HIV 1+2 |
lateral flow recombinant proteins |
whole blood serum/plasma |
D, G |
|
0.67 |
GENEDIA HIV 1/2 Rapid 3.0 (Green Cross) (SEAR & WPR only) |
F3302 |
30 |
18 months/ 2°-30° |
HIV 1+ 2 |
lateral flow recombinant proteins |
whole blood serum/plasma |
D, G |
|
0.70 |
GENIE II HIV-1/HIV-2 (Bio-Rad Laboratories) |
72323 |
40 |
12 months/ 2°-8° |
HIV 1 + 2 |
lateral flow recombinant proteins synthetic peptides |
serum/plasma |
D, G |
€ 2.00 |
|
HIV 1&2 DOUBLECHECK (Orgenics Ltd) |
60332000 |
40 |
15 months/ 4°-8° |
HIV 1+2 |
lateral flow recombinant proteins synthetic peptides |
serum/plasma |
G |
|
1.20 |
HIV TRIDOT (J Mitra & Co., India) |
IR130010 |
10 |
10 months/ 4°-8° |
HIV 1 |
flow through |
serum/plasma |
G |
€ 1.10 |
|
| |
IR130050 |
50 |
|
HIV 2 |
recombinant proteins |
|
|
€ 1.00 |
|
| |
IR130100 |
100 |
|
|
|
|
|
€ 0.90 |
|
| |
IR130200 |
200 |
|
|
|
|
|
€ 0.80 |
|
IMMUNOCOMB II BISPOT HIV1 & 2 (Orgenics Ltd) |
60432002 |
36 |
15 months/ 4°-8° |
HIV 1 HIV 2 |
dipstick synthetic peptides |
serum/plasma |
D, G |
|
1.30 |
INSTANTCHEKTM HIV 1+2 RAPID TEST (EY Laboratories) |
8-1003-40 |
40 |
9 months/ 15°-28° |
HIV 1+2 |
lateral flow |
whole blood |
G |
|
1.09 |
| |
8-1003-100 |
100 |
|
|
|
serum/plasma |
|
|
0.95 |
SERODIA HIV-1/2 (Fujirebio) |
220658 |
100 |
12 months/ 2°-10° |
HIV 1+2 |
agglutination |
serum/plasma |
C, D, G |
¥130 |
(1.19) |
| |
226063 |
220 |
|
|
recombinant proteins |
|
|
¥130 |
(1.19) |
UNI-GOLDTM HIV-1/HIV-2 (Trinity Biotech) |
1206502 |
20 |
9 months/ 2°-27° |
HIV 1+2 |
lateral flow recombinant proteins |
whole blood serum/plasma |
G |
€ 1.15 |
|
Notes:
1 Assays denoted as HIV 1 HIV 2 are able to discriminate between HIV-1 and HIV-2, those denoted as HIV 1+2 are not capable to discrimination
2 Equipment requirements: A: ELISA reader, B: ELISA washer, C: Consumables, D: Pipette, E: Power supply, F: For large volume testing more than 40 samples daily, G:For small volume testing 1 to 40 samples daily, Special Equipment: Bionortesting station required approximate cost US $950
3 Please note that this price does not include freight nor other charges
ELISA ASSAYS
Assay name (Manufacturer) |
Company’s Order Code |
No. of tests per kit |
Guaranteed Shelf-life/Storage temp (°C) |
HIV type1 |
Assay type Antigen |
Sample type |
Equipment requirements2 |
Cost/test3 €/¥ |
Cost/test3 US $ |
ANTI-HIV 1 + 2 ANTIBODIES ELISA DIAGNOSTICS KIT (Shanghai Kehua) (SEARO & WPRO only) |
KH-T-10 |
96 |
5 months/ 2°-8° |
HIV 1+2 |
recombinant proteins synthetic peptides |
4520/620nm |
A, B, C, D, E, F |
|
0.27 |
ENZYGNOST ANTI-HIV 1/2 PLUS (Dade Behring AG) Enzygnost/TMB reagent kit |
OQFK135 |
2 x 96 |
12 months/ 2°-8° |
HIV 1+2 O |
recombinant proteins |
450/650 nm |
A, B, C, D, E, F |
|
0.99 |
| |
OQFK215 |
10 x 96 |
|
|
|
|
|
|
0.75 |
| |
OUVP175 |
960 |
|
|
|
|
|
|
Gratis |
GENEDIA HIV Ag-Ab (Green Cross) (SEARO & WPRO only) |
D1305 |
480 |
12 months/ 2°-8° |
HIV 1+ 2 O HIV Ag |
recombinant proteins synthetic peptides |
450/620nm |
A, B, C, D, E, F |
|
0.40 |
GENSCREEN HIV Ag-Ab (Bio-Rad Laboratories) |
72375 |
96 |
12 months/ 2°-8° |
HIV 1+2 O HIV Ag |
recombinant proteins synthetic peptides |
450/620 nm |
A, B, C, D, E, F |
€ 0.55 |
|
| |
72376 |
480 |
|
|
|
|
|
€ 0.50 |
|
HIV EIA (AniLabsystems Ltd Oy) |
6111011 |
96 |
12 months/ 4°-8° |
HIV 1+2 |
synthetic peptides |
450 nm |
A, B, C, D, E, F |
€ 0.40 |
|
| |
6111012 |
480 |
|
|
|
|
|
€ 0.36 |
|
| |
6111013 |
960 |
|
|
|
|
|
€ 0.34 |
|
MUREX HIV Ag-Ab (Abbott Diagnostics) |
L/N7G79-01 |
96 |
6 months/ 2°-8° |
HIV 1+ 2 O HIV Ag |
recombinant proteins synthetic peptides |
450/620 - 650nm |
A, B, C, D, E, F |
|
1.20 |
| |
L/N7G79-02 |
480 |
|
|
|
|
|
|
0.80 |
UBI HIV-1/2 EIA (United Biomedical) |
680328 |
192 |
14 months/ 2°-8° |
HIV 1+2 |
synthetic peptides |
492/620 nm |
A, B, C, D, E, F |
|
0.40 |
VIRONOSTIKA HIV UNIFORM II PLUS O (bioMérieux BV) |
284017 |
192 |
12 months/ 2°-8° |
HIV 1+2 O |
recombinant proteins synthetic peptides |
450/620 nm |
A, B, C, D, E, F |
€ 0.64 |
|
| |
284018 |
576 |
|
|
|
|
|
€ 0.46 |
|
Notes:
1 Assays denoted as HIV 1 HIV 2 are able to discriminate between HIV-1 and HIV-2, those denoted as HIV 1+2 are not capable to discrimination
2 Equipment requirements: A: ELISA reader, B: ELISA washer, C: Consumables, D: Pipette, E: Power supply, F: For large volume testing more than 40 samples daily, G:For small volume testing 1 to 40 samples daily, Special Equipment: Bionortesting station required approximate cost US $950
3 Please note that this price does not include freight nor other charges
SUPPLEMENTAL ASSAYS
Confirmatory assays
Assay name (Manufacturer) |
Company’s Order Code |
No. of tests per kit |
Guaranteed Shelf-life/Storage temp (°C) |
HIV type1 |
Assay type Antigen |
Sample type |
Equipment requirements2 |
Cost/test3 €/¥ |
Cost/test3 US $ |
HIV BLOT 2.2 (Genelabs Diagnostics) |
11031–036 |
36 |
15 months/ 2°–8° |
HIV 1 HIV 2 |
viral lysate + synthetic peptide |
NA |
C, D, E |
|
10.97 |
INNO-LIATMHIV I/II SCORE (Innogenetics) |
80540 |
20 |
2°–8° |
HIV 1 HIV 2 |
recombinant proteins synthetic peptides |
NA |
D, E |
€ 15.50 |
|
PEPTI-LAV 1–2 (Bio-Rad Laboratories) |
72253 |
10 |
12 months/ 2°–8° |
HIV 1 HIV 2 |
synthetic peptides |
NA |
C, D, E |
€ 15.00 |
|
NEW LAV BLOT I (Bio-Rad Laboratories) |
72252 |
18 |
12 months/ 2°–8° |
HIV 1 |
viral lysate |
NA |
D, E |
€ 13.00 |
|
NEW LAV BLOT II (Bio-Rad Laboratories) |
72252 |
18 |
12 months/ 2°–8° |
HIV 2 |
viral lysate |
NA |
D, E |
€ 13.00 |
|
Notes:
1 Assays denoted as HIV 1 HIV 2 are able to discriminate between HIV-1 and HIV-2, those denoted as HIV 1+2 are not capable to discrimination
2 Equipment requirements: A: ELISA reader, B: ELISA washer, C: Consumables, D: Pipette, E: Power supply, F: For large volume testing more than 40 samples daily, G:For small volume testing 1 to 40 samples daily, Special Equipment: Bionortesting station required approximate cost US $950
3 Please note that this price does not include freight nor other charges
 |
 |
|
|